Xlife Sciences AG (XLS) | WebDisclosure

PRESS RELEASE

published on 11/28/2025 at 13:10, 7 months 2 days ago

Xlife Sciences AG Provides Update on VERAXA Biotech AG’s NASDAQ Listing Process Following U.S. Government Shutdown
Xlife Sciences AG updates on VERAXA Biotech AG's NASDAQ listing process post U.S. Government Shutdown, SEC responds to Form F-4 filing, progress towards business combination with Voyager Acquisition Corp

Nasdaq SEC Xlife Sciences AG VERAXA Biotech AG Voyager Acquisition Corp.
BRIEF

published on 10/16/2025 at 07:05, 8 months 14 days ago

Xlife Sciences AG publie son rapport ESG 2024 mettant en avant la croissance durable

Croissance Durable Responsabilité Sociale Impact Environnemental Xlife Sciences Rapport ESG 2024
BRIEF

published on 10/16/2025 at 07:05, 8 months 14 days ago

Xlife Sciences AG Releases 2024 ESG Report Highlighting Sustainable Growth

Environmental Impact Social Responsibility Sustainable Growth Xlife Sciences ESG Report 2024
PRESS RELEASE

published on 10/16/2025 at 07:00, 8 months 14 days ago

Xlife Sciences AG Publishes 2024 ESG Report: Sustainable Value Creation as a Strategic Core
Xlife Sciences AG publishes 2024 ESG Report showcasing sustainable value creation through integrating ESG principles into corporate strategy and portfolio management in life sciences sector

Life Sciences Xlife Sciences AG ESG Principles Sustainable Value Creation 2024 ESG Report
BRIEF

published on 09/23/2025 at 07:05, 9 months 7 days ago

Xlife Sciences AG Focuses on VERAXA's NASDAQ Listing in H1 2025

Financial Performance Nasdaq Listing Global Partnerships Xlife Sciences Biotech Expansion
BRIEF

published on 09/23/2025 at 07:05, 9 months 7 days ago

Xlife Sciences AG se concentre sur l'introduction de VERAXA au NASDAQ au premier semestre 2025

Performance Financière Partenariats Mondiaux Xlife Sciences Cotation Au Nasdaq Expansion Biotechnologique
PRESS RELEASE

published on 09/23/2025 at 07:00, 9 months 7 days ago

Xlife Sciences AG Half-Year Report 2025: Focus on VERAXA Biotech AG’s NASDAQ Listing and Internationalization
Xlife Sciences AG released its Half-Year Report 2025 with focus on VERAXA Biotech AG's NASDAQ listing and internationalization. Operational and financial highlights were shared along with clear priorities for H2 2025

Nasdaq Listing Xlife Sciences AG Internationalization VERAXA Biotech AG Half-Year Report 2025
BRIEF

published on 07/17/2025 at 07:05, 11 months 13 days ago

VERAXA Biotech AG progresse vers la cotation au NASDAQ grâce au dépôt du formulaire F-4

Cotation Au Nasdaq VERAXA Biotech Regroupement D'entreprises Dépôt Du Formulaire F-4 Thérapeutiques Oncologiques
BRIEF

published on 07/17/2025 at 07:05, 11 months 13 days ago

VERAXA Biotech AG Advances Toward NASDAQ Listing with Form F-4 Filing

Nasdaq Listing Business Combination Oncology Therapeutics VERAXA Biotech Form F-4 Filing
PRESS RELEASE

published on 07/17/2025 at 07:00, 11 months 13 days ago

Xlife Sciences AG’s Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward NASDAQ Listing with Filing of Form F-4
Xlife Sciences AG's portfolio company VERAXA Biotech AG takes a key step towards NASDAQ listing with the filing of Form F-4, signaling continued momentum and billion-dollar valuation in the public market journey

Nasdaq Listing Business Combination Xlife Sciences AG VERAXA Biotech AG Form F-4

Published on 06/30/2026 at 20:55, 33 minutes ago

Clean Air Metals Files Interim Financial Statements for the Three Months Ended April 30, 2026
Published on 06/30/2026 at 18:00, 3 hours 28 minutes ago

PPX Mining Announces Resumption of Diamond Drilling Program at the Callanquitas Mine
Published on 06/30/2026 at 15:00, 6 hours 28 minutes ago

Four Nines Gold Advances Toward Maiden Drill Program with Property-Wide Geophysical Survey at Hayden Hill
Published on 06/30/2026 at 15:00, 6 hours 28 minutes ago

BlackBerry AtHoc Strengthens Enterprise Readiness as Cyber, Climate, and Geopolitical Uncertainty Rises
Published on 06/30/2026 at 15:00, 6 hours 28 minutes ago

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)

View all ACCESSWIRE

Published on 06/30/2026 at 21:00, 28 minutes ago

Europlasma sollicite l’ouverture d’une procédure de redressement judiciaire de sa filiale FDB Industries
Published on 06/30/2026 at 20:43, 45 minutes ago

EQS-Adhoc: BayWa AG: Understanding in principle on a concept for adjusting the restructuring agreement with key creditors and major shareholders
Published on 06/30/2026 at 20:16, 1 hour 11 minutes ago

Finexity AG: FINEXITY publishes final figures for the 2025 financial year
Published on 06/30/2026 at 19:15, 2 hours 13 minutes ago

45 years of OHB: From a five-person operation to a leading European space company
Published on 06/30/2026 at 19:14, 2 hours 13 minutes ago

Block Listing Interim Review

View all EQS

Published on 06/30/2026 at 20:52, 35 minutes ago

Number of shares and voting rights - May 2026 (In French only)
Published on 06/30/2026 at 20:52, 35 minutes ago

Nombre total d'actions et droits de vote - mai 2026
Published on 06/30/2026 at 18:59, 2 hours 29 minutes ago

SUEZ has successfully completed a €600 million green bond issuance
Published on 06/30/2026 at 18:56, 2 hours 32 minutes ago

SUEZ réalise avec succès une émission obligataire verte
Published on 06/30/2026 at 18:33, 2 hours 54 minutes ago

CP de mise à disposition du RA

View all LES ECHOS COMFI WIRE

News